{"id":18789,"date":"2026-02-19T19:50:33","date_gmt":"2026-02-19T19:50:33","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/18789\/"},"modified":"2026-02-19T19:50:33","modified_gmt":"2026-02-19T19:50:33","slug":"as-chinas-drug-industry-races-ahead-its-glp-1-race-is-accelerating-too","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/18789\/","title":{"rendered":"As China\u2019s drug industry races ahead, its GLP-1 race is accelerating, too"},"content":{"rendered":"

For American and European drugmakers, the story of China today is one of a fast-developing market \u2014 one producing not only \u201cme too\u201d therapies but increasingly novel medications as well. And to understand what these shifts might mean for global pharmaceutical companies, look no further than the market for GLP-1 drugs, in particular.<\/p>\n

Earlier this month, Novo Nordisk reported that it saw sales of its diabetes therapy Ozempic decline by 5% in China last year, the first time sales of the medication have fallen since it was approved there in 2021. It\u2019s particularly notable given that sales in all other markets continued to increase \u2014 up 9% in the U.S., 17% in Europe and Canada, and 8% for the rest of the Asia-Pacific region.<\/p>\n

\u201cPretty much all regions did well, with maybe the exception of China. We had higher hopes for China,\u201d Novo CEO Mike Doustdar said in a same-day earnings call.<\/p>\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\"STAT+\"\/<\/p>\n

\t\t\t\t\t
\n\t\t\t\t\t\t\"STAT+\"\/
\n\t\t\t\t\t<\/a><\/p>\n

\t\t\t\tThis article is exclusive to STAT+ subscribers
\n\t\t\t\tUnlock this article \u2014 plus daily coverage and analysis of the biotech sector \u2014 by subscribing to STAT+.<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\t\t\tIndividual plans<\/p>\n

\t\t\t\t\t\tGroup plans<\/p>\n

\t\t\t\tView All Plans<\/a><\/p>\n

\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"For American and European drugmakers, the story of China today is one of a fast-developing market \u2014 one…\n","protected":false},"author":2,"featured_media":18790,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[2759,13188,272,357,358,359],"class_list":{"0":"post-18789","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-biotechnology","9":"tag-chronic-disease","10":"tag-novo-nordisk","11":"tag-obesity","12":"tag-pharmaceuticals","13":"tag-stat"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/18789","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=18789"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/18789\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/18790"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=18789"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=18789"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=18789"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}